肿瘤细胞治疗研究
英文原题：Evolving insights into the improvement of adoptive T-cell immunotherapy through PD-1/PD-L1 blockade in the clinical spectrum of lung cancer.
Evolving insights into the improvement of adoptive T-cell immunotherapy through PD-1/PD-L1 blockade in the clinical spectrum of lung cancer.
我们特别强调近期迎来 30 年的 CIK 细胞治疗，并突出 PD-1/PD-L1 轴在 NSCLC 和 SCLC 中的作用。
癌症免疫疗法拓宽了癌症治疗范围，但仍有部分患者对免疫治疗无应答。肺癌也面临同样问题；其两种主要类型——非小细胞肺癌（NSCLC）和小细胞肺癌（SCLC）——仍是重要临床挑战。过继 T 细胞疗法（ATC）主要包括细胞因子诱导的杀伤（CIK）细胞疗法、CAR-T 细胞疗法和 γδ T 细胞疗法，可增强患者免疫系统抗癌能力。ATC 联合免疫检查点抑制剂（ICI）可进一步提高清除肿瘤的效果。本文特别关注发展已满 30 年的 CIK 细胞疗法，并强调 PD-1/PD-L1 轴在 NSCLC 和 SCLC 中的作用；同时探讨 PD-1/PD-L1 抑制剂与过继 T 细胞免疫疗法之间可能的协同作用，以及二者如何重塑肺癌治疗模式。
Undeniably, cancer immunotherapies have expanded the spectrum of cancer treatment, however, some patients do not respond to immunotherapies. This scenario is no different for lung cancer, whose two main types, non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), still pose a serious clinical challenge. Adoptive T-cell therapies (ATC), which primarily include cytokine-induced killer (CIK) cell therapy, chimeric antigen receptor T-cell (CAR T-cell) therapy and -T-cell therapy, strengthen the patient's immune system in combating cancer. Combining ATC with immune checkpoint inhibitors (ICI) further enhances the effectiveness of this approach to eradicate cancer. With a particular emphasis on CIK cell therapy, which recently completed 30 years, we highlight the role of the PD-1/PD-L1 axis in NSCLC and SCLC. Besides, we provide insights into the potential synergies of PD-1/PD-L1 inhibitors with adoptive T-cell immunotherapy in reshaping the treatment paradigm for lung cancer.
MEMBER ACCOUNT
登录成功会直接打开下一页。
